| Name: | Clonazepam Phthalimido Inhouse Impurity |
| Catalogue No. | VE006731 |
| CAS No. | N/A |
| Molecular Formula | C23H14ClN3O6 |
| Molecular Weight | 463.83 |
| Status | In-stock |
| IUPAC Name | N-(2-(2-chlorobenzoyl)-4-nitrophenyl)-2-(1,3-dioxoisoindolin-2-yl)acetamide |
| Appearance | Off-White to Pale Yellow Solid |
| Description | Clonazepam Phthalimido Inhouse Impurity or N-(2-(2-chlorobenzoyl)-4-nitrophenyl)-2-(1,3-dioxoisoindolin-2-yl)acetamide is a Phthalimido derivative of Clonazepam. Clonazepam depresses seizure activity in many animal models of epilepsy and several types of paroxysmal action in the electroencephalogram of patients. Clonazepam usually limits the spread of discharge from a focal lesion but doesn't suppress the primary focus. |
| References | Malminen, O., and P. Kontro. “γ-Aminobutyric Acid and Benzodiazepine Receptors in Cultured Cerebellar Granule Cells: Effects of Taurine and Its Lipophilic Derivatives.” Neuropharmacology, vol. 28, no. 9, Sept. 1989, pp. 907–12, https://doi.org/10.1016/0028-3908(89)90189-5. Koch-Weser, Jan, and Thomas R. Browne. “Clonazepam.” New England Journal of Medicine, vol. 299, no. 15, Oct. 1978, pp. 812–16, https://doi.org/10.1056/nejm197810122991505. |
